Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase II Trial of Motexafin Gadolinium (MGd) in Patients With Relapsed or Refractory Multiple Myeloma

NCT00096837 is registered in ClinicalTrials.gov with Pharmacyclics LLC. as lead sponsor.

NCT NCT00096837
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00096837 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase II Trial of Motexafin Gadolinium (MGd) in Patients With Relapsed or Refractory Multiple Myeloma
Lead sponsor
Pharmacyclics LLC.
Phase
Phase 2
Overall status
Completed
Start date
Not reported
Completion date
Not reported
Enrollment
25
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma